Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
The farnesoid X receptor (FXR) regulates bile acid, lipid and glucose metabolism. Here we show that treatment of mice with glycine-β-muricholic acid (Gly-MCA) inhibits FXR signalling exclusively in intestine, and improves metabolic parameters in mouse models of obesity. Gly-MCA is a selective high-affinity FXR inhibitor that can be administered orally and prevents, or reverses, high-fat diet-induced and genetic obesity, insulin resistance and hepatic steatosis in mice. The high-affinity FXR agonist GW4064 blocks Gly-MCA action in the gut, and intestine-specific Fxr -null mice are unresponsive to the beneficial effects of Gly-MCA. Mechanistically, the metabolic improvements with Gly-MCA depend on reduced biosynthesis of intestinal-derived ceramides, which directly compromise beige fat thermogenic function. Consequently, ceramide treatment reverses the action of Gly-MCA in high-fat diet-induced obese mice. We further show that FXR signalling in ileum biopsies of humans positively correlates with body mass index. These data suggest that Gly-MCA may be a candidate for the treatment of metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, some data also indicate that antagonism of intestinal FXR signaling could improve metabolic parameters in murine models of NAFLD [256,257].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [256]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beige Adipocytes Are a Distinct Type of Thermogenic Fat Cell in Mouse and Human
Wu, J., Boström, P., Sparks, L. M., Ye, L., Choi, J. H., Giang, A.-H., Khandekar, M., Virtanen, K. A., Nuutila, P., Schaart, G., et al. (2012) · Cell · doi:10.1016/j.cell.2012.05.016 · Cited by 3,319
The RXR heterodimers and orphan receptors
Mangelsdorf, D. J., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90200-7 · Cited by 3,158 · cited 1×
“All individuals fulfilled the following inclusion criteria: (1) no significant alcohol consumption (the definition of significant alcohol consumption has been inconsistent and ranged from 41 alcoholic beverage (10 g of alcohol per one drink unit) per day to 440 g per day); (2) no significant acute or chronic inflammat…”
BackgroundKanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Brown and beige fat: Development, function and therapeutic potential
Harms, M., & Seale, P. (2013) · Nature Medicine · doi:10.1038/nm.3361 · Cited by 2,328
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Self-citationBile acids: regulation of synthesis
Chiang, J. Y. L. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900010-jlr200 · Cited by 1,515
Petrovic, N., Walden, T. B., Shabalina, I. G., Timmons, J. A., Cannon, B., & Nedergaard, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.053942 · Cited by 1,263
Pleiotropic Roles of Bile Acids in Metabolism
de Aguiar Vallim, T. Q., Tarling, E. J., & Edwards, P. A. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.013 · Cited by 1,209
Cited by
Items 301–400 of 566
Role of FXR in Renal Physiology and Kidney Diseases
Guo, Y., Xie, G., & Zhang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032408 · Cited by 34
“It is reported that glycine‐β‐muricholic acid (Gly‐MCA) inhibited FXR signaling exclusively in the intes‐ tine, resulting in a decrease in the serum and intestine ceramide level and an improvement in metabolic dysfunction in obese mice [37].”
BackgroundDynamics of Bile Acid Profiles, GLP-1, and FGF19 After Laparoscopic Gastric Banding
Thöni, V., Pfister, A., Melmer, A., Enrich, B., Salzmann, K., Kaser, S., Lamina, C., Ebenbichler, C. F., Hackl, H., Tilg, H., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00235 · Cited by 29
Pathogenesis of NASH and Promising Natural Products
Leng, Y., Zhang, M., Luo, J., & Zhang, H. (2021) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(21)60002-x · Cited by 34
“Controversially, several studies have suggested that depletion or antagonism of FXR, specifically in the intestine, may have therapeutic potential in NASH ([41-43]).”
BackgroundJiang, J., Ma, Y., Liu, Y., Lu, D., Gao, X., Krausz, K. W., Desai, D. H., Amin, S., Patterson, A. D., Gonzalez, F. J., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.2099 · Cited by 29
Self-citationZhang, Y.-B., Yan, T., Sun, D., Xie, C., Zheng, Y., Zhang, L., Yagai, T., Krausz, K. W., Bisson, W. H., Yang, X., et al. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.080176 · Cited by 28
“Metabolomic analysis was performed on an ultra-performance liquid chromatography coupled Xevo G2 quadrupole time-of-flight mass spectrometer with an ACQUITY UPLC (Waters, Milford, MA) as previously described (Jiang et al., 2015).”
MethodSelf-citationВасильевна, Б. А., Mayorov, A. Y., Mishina, E. Е., Schwartz, A. M., & Belousov, P. V. (2018) · Diabetes Mellitus · doi:10.14341/dm9374 · Cited by 27
Marchianò, S., Biagioli, M., Bordoni, M., Morretta, E., Giorgio, C. D., Vellecco, V., Roselli, R., Bellini, R., Massa, C., Cari, L., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.031241 · Cited by 31
“47 Here, we have confirmed that feeding mice an HFD-F increases bile acid synthesis, as shown by enhanced expression of Cytochrome7a1 and Cytochrome27a1 and increased fecal excretion of C4, a bile acid intermediate used to assess endogenous bile acid synthesis.”
BackgroundWang, C., Yang, Y., Chen, J., Dai, X., Xing, C., Zhang, C., Cao, H., Guo, X., Hu, G., & Zhuang, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417304 · Cited by 29
“TUDCA, a derivative of Ursodeoxycholic acid (UDCA), was used for the treatment of liver dysfunction and increased HFD-induced obesity in a rat model [47,48].”
MethodThe Gastrointestinal Tract as Prime Site for Cardiometabolic Protection by Dietary Polyphenols
Villa-Rodríguez, J. A., Ifie, I., González-Aguilar, G. A., & Roopchand, D. E. (2019) · Advances in Nutrition · doi:10.1093/advances/nmz038 · Cited by 28
“Studies in diabetic mice have established that enteric inhibition of FXR signaling improves glucose intolerance, insulin resistance, and decreases gluconeogenesis by inhibiting the synthesis of gutderived ceramides and their appearance in serum, enhancing beige fat thermogenesis and liver functions (148, 149).”
BackgroundTargeting the gastrointestinal tract to treat type 2 diabetes
Bauer, P. V., & Duca, F. A. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0056 · Cited by 29
A new proposed mechanism of action for gastric bypass surgery: Air hypothesis
Celiker, H. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.08.012 · Cited by 25
Oteng, A., Higuchi, S., Banks, A. S., & Haeusler, R. A. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101326 · Cited by 27
Yang, L., Broderick, D., Campbell, Y., Gombart, A., Stevens, J., Jiang, Y., Hsu, V. L., Bisson, W., & Maier, C. (2016) · Biochimica et Biophysica Acta · doi:10.1016/j.bbapap.2016.08.019 · Cited by 23
“The 3D-coordinates of the FXR-LBD in complex with 3-deoxy-CDCA were retrieved from PDB ID 1OT7 [42] and energetically minimized in the internal coordinate space with Molsoft [43].”
MethodSelf-citationQu, R., Zhang, Y., Kim, B., Zeng, G., Wang, P., Shaoyong, W., Huang, Y., Guo, W., Chen, Y., Wang, P., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.06.002 · Cited by 33
Self-citationThe bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy
Carino, A., Marchianò, S., Biagioli, M., Scarpelli, P., Bordoni, M., Giorgio, C. D., Roselli, R., Fiorucci, C., Monti, M. C., Distrutti, E., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202001386r · Cited by 26
Farnesoid X receptor and fibroblast growth factor 15/19 as pharmacological targets
Maliha, S., & Guo, G. L. (2021) · Liver Research · doi:10.1016/j.livres.2021.02.002 · Cited by 24
Yan, M., Hou, L., Cai, Y., Wang, H., Ma, Y., Geng, Q., Jiang, W., & Tang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.906452 · Cited by 30
Yang, C.-W., Liu, H.-M., Chang, Z., Liu, G.-H., Chang, H., Huang, P., & Lee, T.-Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105274 · Cited by 28
Microbial contributions to chronic inflammation and metabolic disease
Shanahan, F., & Sheehan, D. (2016) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000282 · Cited by 27
“Obesity induced by the microbiota has been shown in experimental mice to be dependent on the FXR receptor [24 & ], but the therapeutic potential of modifying FXR signalling in obesity and hepatic steatosis remains uncertain, with seemingly conflicting results in different experimental settings [25,26].”
BackgroundUrbani, G., Rondini, E., Distrutti, E., Marchianò, S., Biagioli, M., & Fiorucci, S. (2025) · Cells · doi:10.3390/cells14080595 · Cited by 28
“Binding to its FGF receptor (FGFR) on Various FXR agonists are currently developed for clinical applications [220,286–288], although animal studies seem to suggest that FXR antagonists [289–291] might also have a potential therapeutic utility.”
Jiang, J., Zhang, H., Hussain, M., Abdullah, Feng, F., Guan, R., & Zhong, H. (2025) · Biology · doi:10.3390/biology14070802 · Cited by 28
“…against obesity, diabetes, and MASLD through mechanisms such as suppressing hepatic gluconeo-genesis via SHP-independent enterohepatic signaling [87,88] and reducing hepatic lipid accumulation through suppression of SHP and FGF15/FGF19 expression, contrasting evidence highlights the metabolic…”
Hughes, E. P., Wang, X. X., Sabol, L., Barton, K., Hegde, S., Myakala, K., Krawczyk, E., Rosenberg, A. Z., & Levi, M. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00110.2025 · Cited by 29
Luo, Z., Li, M., Yang, J., Li, J., Zhang, Y., Liu, F., El-Omar, E. M., Han, L., Bian, J., Gong, L., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.976638 · Cited by 26
“FXR is responsible for maintaining BAs homeostasis in gastrointestinal tract (30).”
BackgroundSelf-citationGao, Y., Lin, J., Ye, C., Guo, S., & Jiang, C. (2023) · Liver Research · doi:10.1016/j.livres.2023.09.002 · Cited by 36
“118 There was a con fl icting view that acute FXR activation (3 days of treatment with the agonist GSK2324) decreased hepatic TGs, partly by decreasing intestinal lipid absorption by changing the composition of the BA pool and decreasing total biliary and liver BAs.”
Self-citationThe Gut Microbiota, Tumorigenesis, and Liver Diseases
Lv, G., Cheng, N., & Wang, H. (2017) · Engineering · doi:10.1016/j.eng.2017.01.017 · Cited by 25
Dong, Y.-Q., Zhang, X.-Z., Sun, L., Zhang, S., Liu, B., Liu, H., Wang, X., & Jiang, C. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.127 · Cited by 27
Self-citationJia, W. P., & Rajani, C. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8684-7_8 · Cited by 28
Farnesoid X receptor: An important factor in blood glucose regulation
Hou, Y., Fan, W., Yang, W., Samdani, A. Q., Jackson, A. O., & Qu, S.-L. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.03.1626 · Cited by 23
Li, Y., Wang, Y., Zhang, L., Yan, Z., Shen, J., Chang, Y., & Wang, J. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c06456 · Cited by 22
Targeting the Gut Microbiota for Remediating Obesity and Related Metabolic Disorders
Wang, B., Wang, L., Wang, H., Dai, H., Lu, X., Lee, Y. K., Gu, Z., Zhao, J., Zhang, H., Chen, W., et al. (2021) · Journal of Nutrition · doi:10.1093/jn/nxab103 · Cited by 25
Wu, Y., Mo, R., Zhang, M., Zhou, W., & Li, D. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2021.786682 · Cited by 23
“LPS for 5 days; and the GSP+LPS group coupled with a dose of 10 mg/kg BW glycine-β-muricholic acid (Gly-MCA), an intestinal-specific FXR inhibitor (18), for 20 days before LPS injection (Gly + GSP + LPS).”
MethodHost–Microbiota Mutualism in Metabolic Diseases
Fabbiano, S., Suárez-Zamorano, N., & Trajkovski, M. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00267 · Cited by 25
Zhao, S., Lin, H., Li, W., Xu, X., Wu, Q., Wang, Z., Shi, J., Chen, Y., Ye, L., Xi, L., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2462261 · Cited by 26
“24– 26 Previous studies have observed alterations in bile acid profiles after bariatric surgery.”
Self-citationDescribing the fecal metabolome in cryogenically collected samples from healthy participants
Trôst, K., Ahonen, L. L., Suvitaival, T., Christiansen, N. M., Nielsen, T., Thiele, M. S., Jacobsen, S., Krag, A. A., Rossing, P. R., Hansen, T. F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57888-w · Cited by 21
Chen, L., Liu, Y., Tang, Z., Shi, X., Song, Z., Cao, F., Wei, P., Li, M., Li, X., Jiang, D., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111131 · Cited by 25
Self-citationNutritional Approach Targeting Gut Microbiota in NAFLD—To Date
Moszak, M., Szulińska, M., Walczak-Galezewska, M. K., & Bogdański, P. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18041616 · Cited by 23
“Parseus et al. [51] described that the GM was implicated in the bile acid profiles and signaling through the influence of FXR.”
BackgroundInfluentialLiu, Q., Zhang, L., Allman, E. L., Hubbard, T. D., Murray, I. A., Hao, F., Tian, Y., Gui, W., Nichols, R. G., Smith, P. B. W., et al. (2021) · Toxicology · doi:10.1016/j.tox.2021.152831 · Cited by 22
Self-citationYue, H., Cai, W., Li, Y., Feng, X., Dong, P., Xue, C., & Wang, J. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c05411 · Cited by 21
Yang, J.-Y., Liu, M., Lv, L. L., Guo, J.-R., He, K.-Y., Zhang, H., Wang, K., Cui, C.-Y., Yan, B., Du, D., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.932294 · Cited by 25
Lithocholic acid promotes skeletal muscle regeneration through the TGR5 receptor
Sun, L., Fan, L., Tan, W., Zhao, W., Li, Y., Zhu, X., Gao, P., Shu, G., Wang, S., Jiang, Q., et al. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022201 · Cited by 36
“Meanwhile, systemic FXR-knockout mice show significant changes in glucose tolerance and body weight [9,10].”
BackgroundChan, S. H. J., Friedman, E. S., Wu, G. D., & Maranas, C. D. (2019) · Processes · doi:10.3390/pr7070394 · Cited by 22
Liang, L., Zhou, J., Xu, F., Liu, P., Qin, L. F., Liu, L., & Liu, X. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0408-4 · Cited by 21
“MCA, an inhibitor of FXR [36], was used to investigate whether CDCA affected the expression of PepT1 by activating FXR.”
MethodTeno, N., Iguchi, Y., Oda, K., Yamashita, Y., Masuda, A., Fujimori, K., Une, M., & Gohda, K. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00640 · Cited by 23
Nuclear receptors and liver disease: summary of the 2017 basic research symposium
Tran, M., Liu, Y., Huang, W., & Wang, L. (2018) · Hepatology Communications · doi:10.1002/hep4.1203 · Cited by 20
Self-citationTang, M., Su, J., Xu, T., Wang, X., Zhang, D.-M., & Wang, X.-H. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0475-1 · Cited by 22
Gillard, J., Picalausa, C., Ullmer, C., Adorini, L., Staels, B., Tailleux, A., & Leclercq, I. A. (2022) · Nutrients · doi:10.3390/nu14132707 · Cited by 23
“In addition, the reports on the effects of intestinal FXR on GLP-1 are conflicting; some authors showed that FEX induces GLP-1 secretion by enteroendocrine L cells [20], while others showed the exact opposite [35,36] or the absence of effect [37].”
ResultMarchianò, S., Biagioli, M., Roselli, R., Zampella, A., Giorgio, C. D., Bordoni, M., Bellini, R., Morretta, E., Monti, M. C., Distrutti, E., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202101397r · Cited by 21
BMAL1/PGC1α4-FNDC5/irisin axis impacts distinct outcomes of time-of-day resistance exercise
Guo, M., Shen, F., Guo, X., Zhang, J., Ma, Y., Wu, X., Zuo, H., Yao, J., Hu, Y., Wang, D., et al. (2024) · Journal of sport and health science/Journal of Sport and Health Science · doi:10.1016/j.jshs.2024.100968 · Cited by 24
Self-citationThe Role of Gut Microbiota in Host Lipid Metabolism: An Eye on Causation and Connection
Wang, K., Liang, X., Pang, Y., & Jiang, C. (2019) · Small Methods · doi:10.1002/smtd.201900604 · Cited by 19
Self-citationThe Impact of Phytochemicals in Obesity-Related Metabolic Diseases: Focus on Ceramide Metabolism
Kim, E., & Jeon, S. (2023) · Nutrients · doi:10.3390/nu15030703 · Cited by 22
“showed that gut microbiota regulates a bile acid-intestinal FXR signaling that controls ceramide production in the host [64,65].”
BackgroundDai, M., Wan, P., Lin, L., Wu, Z. E., Zhang, T., Zhao, Q., Cheng, Y., Lin, Q., Zhang, B., Liu, A., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155054 · Cited by 20
Self-citationGuthrie, G. J., Kulkarni, M., Vlaardingerbroek, H., Stoll, B., Ng, K., Martin, C. R., Belmont, J. W., Hadsell, D. L., Heird, W. C., Newgard, C. B., et al. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m069526 · Cited by 22
Li, W., Liu, R., Li, X., Tao, B., Zhai, N., Wang, X., Li, Q., Zhang, Y., Gu, W., Wang, W., et al. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12956 · Cited by 20
“Intestinal expression of FXR protects against high-fat diet-induced non-alcoholic fatty liver and obesity.(15,16) Furthermore, the bile acid sequestrant colesevelam, which promotes increased de novo bile acid synthesis, has been approved by the US Food and Drug Administration (FDA) for the treatment of T2D.”
BackgroundResultGut Microbiota and Heart, Vascular Injury
Zeng, C., & Tan, H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2385-4_8 · Cited by 21
Wen, Y., Zou, Z.-Y., Zhao, G., Zhang, M., Zhang, Y., Wang, G., Shi, J., Wang, Y.-Y., Song, Y.-Y., Wang, H., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01329-1 · Cited by 20
Self-citationHost ALDH2 deficiency aggravates nonalcoholic steatohepatitis through gut-liver axis
Li, Z., Kong, C., Mao, Y., Chen, H., Zhang, S., Huang, J., Yao, J.-Q., Cai, P., Xie, N., Han, B., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106902 · Cited by 18
Gut microbiota and bile acids: Metabolic interactions and impacts on diabetic kidney disease
Liu, P., Jin, M., Hu, P., Sun, W., Tang, Y., Wu, J., Zhang, D., Yang, L., He, H., & Xu, X. (2024) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2024.100315 · Cited by 38
Cheng, X. S., Zhou, J., Shi, Z., Yin, Y., Liu, J., Chen, H.-X., Li, P., Liu, L., & Xin, G.-Z. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2019.07.006 · Cited by 18
New drug therapies for metabolic dysfunction-associated steatohepatitis
Chiang, J. Y. L. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.001 · Cited by 19
Zhong, C., Li, H., Lee, S.-Y., Chang, H., Zhang, Y., Threadgill, D. W., Yuan, Y., Zhou, F., Celniker, S., Xia, Y., et al. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-02972-x · Cited by 26
Hasan, M. N., Chen, J., Wang, H., Du, Y., Clayton, Y. D., Gu, L., & Li, T. (2023) · Cells · doi:10.3390/cells12101371 · Cited by 16
“It has also been shown that treating mice with glycine-conjugated βMCA (G-β-MCA), which is not an abundant naturally occurring bile acid in mice, antagonizes intestine FXR signaling and improves metabolic homeostasis in mice [17].”
BackgroundMethodInfluentialWang, L., Gao, C. Y., Yang, L., Wang, C., Wang, B., Wang, H., Shu, Y., & Yan, Y. (2023) · Aquaculture Reports · doi:10.1016/j.aqrep.2023.101848 · Cited by 23
Bile acids attenuate hepatic inflammation during ischemia/reperfusion injury
Huang, K., Wang, C., Mei, B., Li, J., Ren, T., Zhan, H., Zhang, Y., Zhang, B., Lv, X., Zhang, Q., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101101 · Cited by 20
“38,39 Similar to T b MCA, Gly-b MCA bound to S1PR2 (Fig.”
Self-citationChen, M., Gao, M., Wang, H., Chen, Q., Liu, X., Mo, Q., Huang, X., Ye, X., & Zhang, D. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155806 · Cited by 18
Biological functions and pharmacological behaviors of bile acids in metabolic diseases
Zhuang, T., Wang, X., Wang, Z., Gu, L., Yue, D., Wang, Z., Li, X., Yang, L., Huang, W., & Ding, L. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.11.003 · Cited by 29
“In addition, glycine-b -muricholic acid (Gly-b -MCA) is identified as a high-affinity, selective FXR inhibitor that can block FXR signaling in an intestine-specific manner, thus improving metabolic parameters in obese animals [101].”
Cai, H., Lin, M. F., Chen, K., Wu, Y., Le, T. N., Zhang, J., & Zhao, M. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106628 · Cited by 22
Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
Finan, B., Parlee, S. D., & Yang, B. S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101153 · Cited by 17
“Despite clear directions in which way to modulate hepatic FXR action for beneficial pharmacological effects, debate exists about whether to agonize or antagonize intestinal FXR for systemic metabolic benefits [54,55].”
BackgroundThe microbial metabolome in metabolic‐associated fatty liver disease
Li, M., Rajani, C., Zheng, X., & Jia, W. P. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15746 · Cited by 17
Role of gut microbiota in the development of non-alcoholic fatty liver disease
Wang, X., Xia, J., & Jiang, C. (2019) · Liver Research · doi:10.1016/j.livres.2019.01.006 · Cited by 17
Self-citationBile acid modulation of host immunity
Anh, N. B., Yang, X., & Hang, H. C. (2025) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.70014 · Cited by 17
“30 Interestingly, the conjugated primary bile acids in mice, tauro-β -muricholic acid 31 and glyco-β - muricholic acid, 32 neither of which are found in humans, act as FXR antagonists, raising questions about the translational relevance of bile acid-related studies in mice for human physiology.”
Chen, C., Zhang, B., Tu, J., Peng, Y., Zhou, Y., Yang, X., Yu, Q.-M., & Tan, X. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115992 · Cited by 18
Zhi, N., Chang, X., Wang, X., Guo, J. X., Chen, J., & Gui, S. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1341583 · Cited by 17
Cash, J. G., Konaniah, E. S., Hegde, N. V., Kuhel, D. G., Watanabe, M., Romick‐Rosendale, L. E., & Hui, D. Y. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.07.009 · Cited by 16
“The metabolic benefits of intestinal FXR inhibition have also been noted previously [39].”
BackgroundDysbiosis and liver diseases (Review)
Nishikawa, H., Fukunishi, S., Asai, A., Yokohama, K., Ohama, H., Nishiguchi, S., & Higuchi, K. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.5016 · Cited by 15
Zhang, N., Wu, Y., Zhong, W., Xia, G., Xia, H., Wang, L., Wei, X.-H., Li, Y., Shang, H., He, H., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154148 · Cited by 17
Quantitative Analysis of Bile Acid with UHPLC-MS/MS
Tian, Y., Cai, J., Allman, E. L., Smith, P. B. W., & Patterson, A. D. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0849-4_15 · Cited by 17
Self-citationЗагоскин, П. П., & Erlykina, E. I. (2020) · Современные технологии в медицине · doi:10.17691/stm2020.12.5.13 · Cited by 19
Intestinal farnesoid X receptor signaling controls hepatic fatty acid oxidation
Lu, D., Liu, Y., Luo, Y., Zhao, J., Feng, C., Xue, L., Xu, J., Wang, Q., Yan, T., Xiao, P., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159089 · Cited by 18
Self-citationZhang, Y., Huang, Y., Fan, J., Zhang, M., Hasan, A., Yang, Y., Yu, R., Zhou, X., Ye, M., & Qiao, X. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c02086 · Cited by 14
Ouyang, J., Li, X., Liu, C., Ou-yang, J., Tang, J., Liu, Q., Huang, J., & Liu, Z. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105766 · Cited by 14
Xiong, X., Gu, X., Li, X., Jia, K., Wei, Y., & Zhao, R. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.342119 · Cited by 15
Impact of cholecystectomy on the gut-liver axis and metabolic disorders
Raposo, M. A., Oliveira, E., Santos, A., Guadagnini, D., Mourabit, H. E., Housset, C., Lemoinne, S., & Saad, M. J. A. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102370 · Cited by 18
Li, D.-X., Xu, S.-Q., Jiang, H., Li, Y., Zhao, Y., Jin, P., Ji, S., Du, Y., & Tang, D. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106600 · Cited by 15
Cholic Acid Feeding Leads to Increased CYP2D6 Expression in CYP2D6-Humanized Mice
Pan, X., Kent, R., Won, K., & Jeong, H. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074013 · Cited by 16
“, 2009) or hepatic nutrient metabolism (Jiang et al., 2015).”
BackgroundCeramide dependent lipotoxicity in metabolic diseases
Li, Y., Tippetts, T. S., & Chaurasia, B. (2017) · Nutrition and Healthy Aging · doi:10.3233/nha-170032 · Cited by 16
“demonstrated that ectopic ceramides inhibit the browning of beige adipocytes, suggesting that endogenous ceramides could be autonomous regulators of adipocyte function [59].”
BackgroundIntestinal microbiota-farnesoid X receptor axis in metabolic diseases
Zou, B., Yang, W., Tang, Y., Hou, Y., Tang, T., & Qu, S.-L. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.06.006 · Cited by 15
Miyata, M., Tanaka, T., Takahashi, K., Funaki, A., & Sugiura, Y. (2021) · Amino Acids · doi:10.1007/s00726-021-03068-7 · Cited by 14
Bile Acid-Induced Liver Injury in Cholestasis
Li, T., & Chiang, J. Y. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-53774-0_7 · Cited by 16
Zhou, H., Huang, Y., Chen, C., Song, M., & Hylemon, P. B. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100120 · Cited by 19
Mezhibovsky, E., Tveter, K. M., Villa-Rodríguez, J. A., Bacalia, K., Kshatriya, D., Desai, N., Cabales, A. J., Wu, Y., Sui, K., Duran, R. M., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad095 · Cited by 12
“Inhibition of FXR is being investigated as a potential treatment for cholestasis and glucose intolerance [95, 96].”
BackgroundUncovering the Gut–Liver Axis Biomarkers for Predicting Metabolic Burden in Mice
Yang, G., Liu, R., Rezaei, S., Liu, X., & Wan, Y. Y. (2023) · Nutrients · doi:10.3390/nu15153406 · Cited by 15
Tailoring FXR Modulators for Intestinal Specificity: Recent Progress and Insights
Morrison, A., & Elgendy, B. (2024) · Molecules · doi:10.3390/molecules29092022 · Cited by 14
“Notably, Gly-MCA ( 6 ) demonstrates favorable pharmacokinetic properties, such as oral bioavailability and resistance to hydrolysis by gut bacterial bile salt hydrolase [26].”
BackgroundChen, J., Yang, H., Qin, Y., Zhou, X., & Ma, Q. (2024) · Research · doi:10.34133/research.0515 · Cited by 20
Qamar, M. T. U., Mirza, M. U., Song, J., Rao, M. J., Zhu, X.-T., & Chen, L. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.116895 · Cited by 13
Treatment of insulin resistance: straight from the gut
Zhang, X., Zheng, X., & Yuan, Y. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.06.016 · Cited by 13
ApoE is a major determinant of hepatic bile acid homeostasis in mice
Hardenberg, S. V., Gnewuch, C., Schmitz, G., & Borlak, J. T. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.09.008 · Cited by 13
The Physiological Importance of Bile Acid Structure and Composition on Glucose Homeostasis
Higuchi, S. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01329-5 · Cited by 13
A critical role for Phocaeicola vulgatus in negatively impacting metformin response in diabetes
Chen, M., Peng, Y., Hu, Y., Kang, Z., Chen, T., Zhang, Y., Chen, X., Li, Q., Yuan, Z., Wu, Y., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.02.008 · Cited by 15
“To reiterate the interrelationship between FXR e DRP1 e lipid accumulation and thermogenic damage, glycine-b -muricholic acid (Gly-b -MCA), an intestinal FXR-specific inhibitor that has been proven ineffective in intestine-specific Fxr -null mice 18 , was validated.”
Lallement, J., Raho, I., Merlen, G., Rainteau, D. P., Croyal, M., Schiffano, M., Kassis, N., Doignon, I., Soty, M., Lachkar, F., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2023.159333 · Cited by 18
“Interestingly, inhibition of intestinal FXR signaling prevents obesity induced by high fat diet and metabolic disease such as insulin resistance and fatty liver [19].”
BackgroundLi, L., Yang, S., Liang, X., Liu, Y., Xu, H., Guo, X., Xie, C., & Xu, X. (2023) · Food Science and Human Wellness · doi:10.26599/fshw.2022.9250218 · Cited by 14
Self-citation
Metadata
- Authors
- Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K. W., Shi, J., Brocker, C. N., Desai, D., Amin, S. G., Bisson, W. H., Liu, Y., Gavrilova, O., Patterson, A. D., & Gonzalez, F. J.
- Affiliations
- National Institutes of Health (US)
- Peking University (CN)
- Peking University People's Hospital (CN)
- Pennsylvania State University (US)
- Oregon State University (US)
- Corresponding author
- Patterson, Andrew D.
- Gonzalez, Frank J.
- ORCID
- Venue
- Nature Communications
- Published
- 2015-12-15
- Volume
- 6
- Issue
- 1
- Pages
- 10166-10166
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4682112
- OpenAlex
- W2236340720
- Cited by
- 559
- References
- 58
- Citations by year
- 2026: 33 · 2025: 55 · 2024: 54 · 2023: 49 · 2022: 56 · 2021: 78 · 2020: 61 · 2019: 52 · 2018: 39 · 2017: 49 · 2016: 32
- FWCI
- 17.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Greater South Information System
- Funders
- Pennsylvania Department of Health
- National Natural Science Foundation of China (31401011, 81200626)
- National Institutes of Health
- National Cancer Institute
- National Institute of Environmental Health Sciences (R01ES022186, ES022186)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- farnesoid X receptor, obesity, insulin resistance, hepatic steatosis, ceramide biosynthesis, high-fat diet-induced obesity, bile acid metabolism, GW4064, ileum, metabolic dysfunction
- MeSH terms
- Receptor, Farnesoid X-Activated, Adolescent, Adult, Aged, Animals, Ceramides, Cholic Acids, Fatty Liver, Female, Glycine, Humans, Ileum, Insulin Resistance, Intestinal Mucosa, Isoxazoles, Liver, Male, Middle Aged, Obesity, Receptors, Cytoplasmic and Nuclear, Mice, Young Adult, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.